NEUROENDOCRINE CARCINOMA

This study is testing whether a combination of two immunotherapy drugs, atezolizumab and bevacizumab, can help control several rare types of advanced solid tumors. The trial is for adults whose cancer has spread or returned after other treatments. The goal is to see if this drug …

This study is testing a new drug called HPN328, both alone and in combination with other cancer drugs, for people with advanced cancers that have a specific marker called DLL3. The main goals are to find safe and effective doses and to see how well the treatments work. The trial …

This study is testing whether combining two drugs, niraparib and dostarlimab, can help control recurrent small cell lung cancer and other aggressive neuroendocrine cancers. It is for adults whose cancer has returned after at least one prior treatment. The goal is to see if this c…

This study is testing if combining a targeted, high-dose radiation treatment with an immunotherapy drug works better than radiation alone for certain early-stage or recurrent non-small cell lung cancers. About 140 participants will be randomly assigned to receive either the radia…

This early-stage trial is testing the safety and effectiveness of a modified virus (VSV-IFNβ-NIS) when given alongside standard immunotherapy drugs (like pembrolizumab or nivolumab/ipilimumab). It is for adults with specific advanced solid tumors—including non-small cell lung can…

This study is testing an experimental oral drug called CVM-1118 for people with advanced neuroendocrine tumors that have stopped responding to standard treatments. The main goal is to see if the drug can slow or stop the cancer from growing. Researchers will also closely monitor …

This study is testing whether combining two existing drugs—nivolumab (an immunotherapy) and temozolomide (a chemotherapy)—can help control cancers that have come back or stopped responding to standard treatments. It is for adults with recurrent small-cell lung cancer or advanced …

This study is creating a registry to collect information and blood samples from 400 people with neuroendocrine tumors. The main goal is to see how well a specific blood test, called NETest, can help doctors detect the cancer early, monitor if it comes back, and predict how patien…

This study aims to understand how different treatment sequences affect the quality of life and symptoms of people with neuroendocrine tumors (NETs). Researchers will follow over 2,500 patients for up to five years, linking their survey answers about their health and treatment exp…

This study is using a special type of PET scan to look at a specific target on aggressive neuroendocrine cancer cells in the digestive tract. Researchers want to see if enough of this target is present to potentially use a targeted radiation treatment in the future. The study inv…